These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19660790)

  • 1. In retinal vein occlusion platelet response to thrombin is increased.
    Leoncini G; Signorello MG; Segantin A; Giacobbe E; Armani U; Piana A; Camicione P
    Thromb Res; 2009 Dec; 124(6):e48-55. PubMed ID: 19660790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet activation by collagen is increased in retinal vein occlusion.
    Leoncini G; Bruzzese D; Signorello MG; Armani U; Piana A; Ghiglione D; Camicione P
    Thromb Haemost; 2007 Feb; 97(2):218-27. PubMed ID: 17264950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skepinone-L, a novel potent and highly selective inhibitor of p38 MAP kinase, effectively impairs platelet activation and thrombus formation.
    Borst O; Walker B; Münzer P; Russo A; Schmid E; Faggio C; Bigalke B; Laufer S; Gawaz M; Lang F
    Cell Physiol Biochem; 2013; 31(6):914-24. PubMed ID: 23817201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
    Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
    Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of resistance to APC in young patients with retinal vein occlusion.
    Kuhli C; Hattenbach LO; Scharrer I; Koch F; Ohrloff C
    Graefes Arch Clin Exp Ophthalmol; 2002 Mar; 240(3):163-8. PubMed ID: 11935272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Retinal vein occlusion and lipoprotein (a)].
    Ribeaudeau-Saindelle F; Glacet-Bernard A; Lelong F; Coscas G; Soubrane G
    J Fr Ophtalmol; 1998 Apr; 21(4):245-50. PubMed ID: 9759412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of protein tyrosine phosphorylation after retinal branch vein occlusion in cats.
    Hayashi A; Imai K; Kim HC; de Juan E
    Invest Ophthalmol Vis Sci; 1997 Feb; 38(2):372-80. PubMed ID: 9040470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated protein C resistance is a risk factor for central retinal vein occlusion.
    Marcucci R; Bertini L; Liotta AA; Rogolino A; Antonucci E; Ilari I; Pepe G; Prisco D
    Ann Ital Med Int; 2000; 15(3):195-8. PubMed ID: 11059059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion.
    Weger M; Stanger O; Deutschmann H; Temmel W; Renner W; Schmut O; Semmelrock J; Haas A
    Graefes Arch Clin Exp Ophthalmol; 2002 Apr; 240(4):286-90. PubMed ID: 11981642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperhomocysteinaemia: risk of retinal vascular occlusion.
    Yaghoubi GH; Madarshahian F; Mosavi M
    East Mediterr Health J; 2004; 10(4-5):633-9. PubMed ID: 16335656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevalence of glaucoma suspect in patients with central vein occlusion].
    Călugăru M; Călugăru D
    Oftalmologia; 2001; 51(1):80-4. PubMed ID: 11519342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blunted inhibition by insulin of agonist-stimulated calcium, pH and aggregatory responses in platelets from hypertensive patients.
    Touyz RM; Schiffrin EL
    J Hypertens; 1994 Nov; 12(11):1255-63. PubMed ID: 7868873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein Z levels and central retinal vein or artery occlusion.
    Koren-Michowitz M; Eting E; Rahimi-Levene N; Garach-Jehoshua O; Volcheck Y; Kornberg A
    Eur J Haematol; 2005 Nov; 75(5):401-5. PubMed ID: 16191090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mechanism of anti-platelet activity of davallialactone: involvement of intracellular calcium ions, extracellular signal-regulated kinase 2 and p38 mitogen-activated protein kinase.
    Kim SD; Lee IK; Lee WM; Cho JY; Park HJ; Oh JW; Park SC; Kim SK; Kwak YS; Yun BS; Rhee MH
    Eur J Pharmacol; 2008 Apr; 584(2-3):361-7. PubMed ID: 18313047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet aggregation, platelet cAMP levels and thromboxane B2 synthesis in patients with diabetes mellitus.
    Chen SY; Yu BJ; Liang YQ; Lin WD
    Chin Med J (Engl); 1990 Apr; 103(4):312-8. PubMed ID: 2167823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion.
    Hayreh SS; Zimmerman MB; Beri M; Podhajsky P
    Ophthalmology; 2004 Jan; 111(1):133-41. PubMed ID: 14711725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma homocysteine and cysteine levels in retinal vein occlusion.
    Pinna A; Carru C; Zinellu A; Dore S; Deiana L; Carta F
    Invest Ophthalmol Vis Sci; 2006 Sep; 47(9):4067-71. PubMed ID: 16936125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of magnesium lithospermate B on aggregation and 5-HT release in rabbit washed platelets.
    Wang W; Wang YP; Sun WK; Xu YM; Xuan LJ
    Acta Pharmacol Sin; 2000 Sep; 21(9):859-63. PubMed ID: 11501172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk factors in central retinal vein occlusion].
    Călugăru D
    Oftalmologia; 2011; 55(2):27-37. PubMed ID: 21888066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro glycoxidized low-density lipoproteins and low-density lipoproteins isolated from type 2 diabetic patients activate platelets via p38 mitogen-activated protein kinase.
    Calzada C; Coulon L; Halimi D; Le Coquil E; Pruneta-Deloche V; Moulin P; Ponsin G; Véricel E; Lagarde M
    J Clin Endocrinol Metab; 2007 May; 92(5):1961-4. PubMed ID: 17341567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.